Current efforts toward achieving a cure for HIV are focused on developing strategies to eliminate latently infected CD4+ T cells, which represent the major barrier to virus eradication. Sensitive, precise, and practical assays that can reliably characterize and measure this HIV reservoir and can reliably measure the impact of a candidate treatment strategy are essential. PCR-based procedures for detecting integrated HIV DNA will overestimate the size of the reservoir by detecting replication-incompetent proviruses; however, viral outgrowth assays underestimate the size of the reservoir. Here, we describe the attributes and limitations of current procedures for measuring the HIV reservoir. Characterizing their relative merits will require rigorous evaluation of their performance characteristics (sensitivity, specificity, reproducibility, etc.) and their relationship to the results of clinical studies.
Measuring the latent reservoir in vivo

Marta Massanella and Douglas D. Richman

UCSD, La Jolla, California, USA. 1VA San Diego Healthcare System, La Jolla, California, USA.

Current efforts toward achieving a cure for HIV are focused on developing strategies to eliminate latently infected CD4+ T cells, which represent the major barrier to virus eradication. Sensitive, precise, and practical assays that can reliably characterize and measure this HIV reservoir and can reliably measure the impact of a candidate treatment strategy are essential. PCR-based procedures for detecting integrated HIV DNA will overestimate the size of the reservoir by detecting replication-incompetent proviruses; however, viral outgrowth assays underestimate the size of the reservoir. Here, we describe the attributes and limitations of current procedures for measuring the HIV reservoir. Characterizing their relative merits will require rigorous evaluation of their performance characteristics (sensitivity, specificity, reproducibility, etc.) and their relationship to the results of clinical studies.

Introduction

Research focused on the eradication of HIV has highlighted the need for sensitive, precise, and practical assays to monitor the HIV reservoir. A latently infected cell contains a viral genome in a dormant state, from which virus replication can be induced. The latent HIV reservoir is comprised of those cells from which a replication-competent form of HIV can be induced in vivo. Latent proviruses are found in all CD4+ T cell subsets, but they are predominantly housed in the resting memory T cell subset (1–3). Approximately 1 in 10^{10}–10^{14} CD4+ T cells is latently infected in most patients, with the rate of infection primarily depending on when antiretroviral therapy (ART) was started after infection and the individual’s HIV viral load set point (4). This set of cells may represent only 10^{4}–10^{7} latently infected cells in the whole body, assuming a total of 10^{11} CD4+ T lymphocytes (5). These low frequencies highlight the many technical and practical challenges for measuring the HIV reservoir. The technical challenges require the assay to be (i) sensitive enough to detect small numbers in a background of a large number of cells, (ii) specific so that a rare event is a true event, and (iii) capable of distinguishing between replication-competent and -incompetent proviruses. Additionally, an assay must have the precision to permit a robust detection of a reduction in the HIV reservoir when assessing a candidate intervention for eradication. The practical challenges are to obtain enough cells to measure the rare events and to obtain enough rare events to measure a reduction. Because many assays are close to the limit of detection, the dynamic range that makes it possible to measure a reduction is usually quite small. Moreover, the coefficient of variation of assays almost always increases as they approach the limit of detection, making the interpretation more challenging. Another practical challenge is that only 1%–2% of the body’s lymphocytes are in the circulation (6). Over 98% of lymphocytes are in tissues that are more difficult to access; moreover, their distribution in those tissues is not mixed and homogeneous, as in the circulation. Finally, reports of assays in most publications fail to incorporate rigorous descriptions of performance characteristics such as sensitivity, specificity, or reproducibility, with the consequence that many assertions about the size or changes in the HIV reservoir may not be dependable.

To date, there has been no convincing cellular marker that distinguishes the rare latently infected cell from uninfected cells. Measurements of the various forms of HIV-specific nucleic acids, which can be extracted or induced from latency and then detected, are typically the most sensitive. Despite this higher sensitivity, these assays fail to distinguish defective proviral genomes or other replication-incompetent forms of the virus. Terminal-dilution coculture assays (7–9) of replication-competent virus consistently detect only one infectious unit per hundreds of HIV proviral genomes (10). It is unclear how much of this low proportion is attributable to replication-incompetent proviruses and how much is attributable to suboptimal sensitivity of quantitative viral outgrowth assays (QVOA) for the detection of replication-competent, latently infected cells. The various assays that have been reported to date are summarized below, with attempts to characterize their applications, attributes, and limitations (Table 1).

PCR-based assays to measure the latent reservoir

The most sensitive, quickest, and easiest assays to measure the prevalence of HIV infected cells are PCR based (Figure 1A). These assays quantify total or integrated HIV DNA or HIV RNA transcripts.

HIV DNA: Total, integrated, and 2-LTR circles. The most common method for measuring HIV DNA is quantitative PCR (qPCR) for total DNA, which includes integrated and nonintegrated forms. Typically, qPCR is performed on DNA extracted from total peripheral blood mononuclear cells (PBMCs) or enriched CD4+ T cells using PCR primers and probes targeting conserved regions of the HIV genome (Pol or Gag) (10, 11). A standard curve is constructed with known copy numbers of proviral DNA (for example, using a plasmid standard such as...
PCR assays

<table>
<thead>
<tr>
<th>Assay</th>
<th>Detection method</th>
<th>Days</th>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV DNA</td>
<td>qPCR or ddPCR</td>
<td>1</td>
<td>Easy, fast, and sensitive. Does not require cell culture.</td>
<td>The majority of proviruses detected are defective.</td>
</tr>
<tr>
<td>Integrated proviral DNA</td>
<td>qPCR</td>
<td></td>
<td>Direct cell lysis reduces input cell numbers. ddPCR more precise than qPCR and absolute quantification.</td>
<td></td>
</tr>
<tr>
<td>2-LTR circles, as a marker of residual replication</td>
<td>qPCR or ddPCR</td>
<td>Total HIV DNA; quantifies integrated and unintegrated HIV DNA (i.e., 2-LTR Circles)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV RNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>us</td>
<td>qRT-PCR or ddPCR</td>
<td>1</td>
<td>Easy</td>
<td>Does not quantify all latently infected cells.</td>
</tr>
<tr>
<td>ms</td>
<td>qRT-PCR or ddPCR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poly-A</td>
<td>qRT-PCR or ddPCR</td>
<td>Poly-A: detects fully elongated HIV transcripts</td>
<td>Detection of defective proviruses</td>
<td></td>
</tr>
<tr>
<td>Residual viremia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>qRT-PCR</td>
<td>1</td>
<td>Measure of residual virus production during ART</td>
<td>Time consuming; Low dynamic range; Close to the limit of detection (with 8 ml of plasma); Does not directly measures the latent reservoir</td>
<td></td>
</tr>
</tbody>
</table>

Culture Assays

<table>
<thead>
<tr>
<th>Assay</th>
<th>Detection method</th>
<th>Days</th>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td>QVOA</td>
<td></td>
<td>9–21</td>
<td>Measures only replication-competent virus; Increased sensitivity for RT-PCR assay compared with the p24 detection, without detection of defective proviruses; The use of MOLT-4/CCR5 reduces time of culture</td>
<td>Long protocol; Low dynamic range; Great variability due to donor variability (improved with MOLT-4/CCR5); Requires large number of cells; Not all intact proviruses get reactivated</td>
</tr>
<tr>
<td>Inducible transcription assays</td>
<td></td>
<td>2–7</td>
<td>No need for outgrowth of virus before measurement; Faster than QVOA; ddPCR more precise than RT-PCR; TILDA: requires less cells</td>
<td>May detect some defective proviruses. Does not measure replication competent viruses.</td>
</tr>
</tbody>
</table>

pNL4-3), and values are normalized to the total cell number using a cellular gene (present as two copies per diploid cell) to calculate the number of infected cells. Several laboratories have improved this method in different ways. First, column-based DNA extraction protocols are inefficient and inconsistent. A direct cell lysis protocol using diverse detergents and/or proteinase K improves the efficiency of nucleic acid recovery; therefore, it is possible to reduce cell input to study cell populations with lower cell numbers accurately (1, 3, 12–15). Second, qPCR limits assay accuracy at low copy numbers by exponentially amplifying noise. Droplet digital PCR (ddPCR) has been proposed as an alternative to qPCR, with potentially improved accuracy and precision (16, 17).

Total HIV DNA includes stably integrated proviruses and extrachromosomal HIV DNA forms, which can be quantified separately. Alu PCR is the most common method to measure integrated HIV DNA (12, 18–21). With this protocol, one primer binds to the highly repetitive Alu elements in the human genome and the second targets the HIV Gag or long terminal repeat (LTR), after which nested PCR is used to enhance sensitivity using a second set of primers in the HIV LTR. A standard curve is required to quantify the levels of integrated HIV DNA, which can include a mixture of DNA from cells with different HIV integration sites at different distances from an Alu element. A correction factor can be used to account for proviruses that are too far from an Alu sequence to be detected. HIV-integrated DNA strongly correlated with total HIV DNA measured by ddPCR (10), indicating that most of the HIV DNA in ART-suppressed subjects is integrated. Integrated DNA modestly correlates with QVOA (10), and it might prove to be a more useful tool than total HIV DNA to estimate the size of an HIV reservoir when there is prolonged persistence or new accumulation of unintegrated DNA (i.e., 2-LTR circles). Integrated proviruses can also be measured using physical separation of high molecular weight (chromosomal) DNA (22), a linker-primer PCR assay (23), or inverse PCR (7).

Total HIV DNA PCR measurements can also detect other forms of unintegrated DNA, such as 1-LTR and 2-LTR circles, which are the
Polyproteins for the Pol and Gag gene products, and it is incorporated into virions as genomic RNA. The different single-spliced mRNAs are translated into the envelope proteins, as well as other accessory proteins (Vif, Vpr, and Vpu), which will assemble into the budding virion. The vast majority of cells harboring latent HIV do not transcribe viral RNA; however, us- and msRNA have been detected in ART-treated subjects, even in cells that do not produce viral particles (34). usRNA is more abundant and therefore more easily detected; however, short HIV Gag RNA transcripts are more commonly produced (35). In contrast, the presence of msRNA reflects the ability of the cell to produce virus, but its presence does not imply productive replication per se (36). A temporal shift toward a higher msRNA/usRNA ratio in ART-treated subjects might be used as a biomarker of residual replication. Cell-associated RNA (caRNA) can be measured from extracted RNA of total PBMCs or enriched CD4+ T cells. usRNA can be easily detected with a seminested or nested quantitative reverse transcription PCR (qRT-PCR) (36–39) or ddPCR, using a set of primers and probe against Pol or Gag (17, 30, 33, 39). Alternatively, some investigators have adapted commercial quantitative tests for HIV-1 plasma viremia, such as Amplicor (Roche Diagnostics) (40, 41) or APTIMA HIV-1 Qualitative assay (Hologic) (42, 43) for the quantitation of caRNA. msRNA primers are designed to amplify a region containing the Ta t/Rev (or Tat/Nef) exon-exon junction and can be quantified by nested qRT-PCR (36, 38, 39) or ddPCR (17, 39, 44). An assay to specifically quantify correctly terminated HIV-1 transcripts has been developed using a primer/probe against the polyadenylated tail present in mRNAs and HIV 3’-LTR, and it can be used in a qRT-PCR or ddPCR platform (17, 45, 46).

Plasma viremia, cell-free RNA. Despite the fact that ART can sustain suppression of virus replication below the level of detection of standard clinical assays for decades, more sensitive assays interrogating larger volumes of plasma can detect virion-associated HIV RNA in most subjects who are well suppressed on ART (47). In most subjects, this viremia is sustained for years at levels below 10 copies per ml plasma (48, 49). Evidence has been generated that at least some of these virions could be replication competent (50), but there is little evidence that this low-level viremia has undergone posttherapy evolution or has acquired drug resistance (51, 52), suggesting that there is viral production from persistently infected host cells or from the population of latently infected cells that is under-
Poissonian statistics (42). is based on the proportion of aliquots providing a signal using assay) to test 0.5-ml aliquots of plasma extract; quantitation automated transcription-mediated amplification assay (TMA approach is under investigation that utilizes a highly sensitive, by a qPCR assay with a standard control (48, 56). A second involvement the ultracentrifugation of 3–10 ml of plasma, followed this reservoir requires a large volume of plasma and cumbered to achieve eradication. The challenge is that measuring clearly defined, its presence indicates a reservoir that must be some procedures, and such measurements have a wide coefficient of variation (48, 56). As a measure of a latent reservoir, going a steady state of activation and self-renewal. The detection of clonal populations among sequences in the same patient, even at different time points (53), provided the first evidence for a clonally proliferating infected cell population, which has subsequently been confirmed by the documentation of multiple clones of proviral integration sites (54, 55).

Although the source of this low-level viremia has not been clearly defined, its presence indicates a reservoir that must be purged to achieve eradication. The challenge is that measuring this reservoir requires a large volume of plasma and cumbersome procedures, and such measurements have a wide coefficient of variation (48, 56). As a measure of a latent reservoir, it also provides a very small dynamic range to assess the effectiveness of a candidate intervention. The assay as conducted involves the ultracentrifugation of 3–10 ml of plasma, followed by a qPCR assay with a standard control (48, 56). A second approach is under investigation that utilizes a highly sensitive, automated transcription-mediated amplification assay (TMA assay) to test 0.5-ml aliquots of plasma extract; quantitation is based on the proportion of aliquots providing a signal using Poissonian statistics (42).

# Table 2. Comparison of QVOAs and inducible RNA assays

<table>
<thead>
<tr>
<th>References</th>
<th>Subjects</th>
<th>Samples</th>
<th>Activation method</th>
<th>Feeder cells</th>
<th>Duration (days)</th>
<th>Dilutions</th>
<th>Dilution factor</th>
<th>Replicates</th>
<th>Cells 1st dilution</th>
<th>Total cells tested</th>
<th>Detection method</th>
<th>RNA extraction methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>rCD4 T cells</td>
<td>PHA-irradiated PBMCs (10-fold excess) + IL-2</td>
<td>1×10⁶ CD8dPBMCs activated with PHA (1 or more donors)</td>
<td>14</td>
<td>5</td>
<td>5</td>
<td>2</td>
<td>5×10⁶</td>
<td>12.5×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>68</td>
<td>rCD4 T cells</td>
<td>PHA-irradiated PBMCs (10-fold excess) + IL-2</td>
<td>1×10⁶ CD8dPBMCs activated with PHA (1 or more donors)</td>
<td>14</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>1×10⁶</td>
<td>2.5×10⁶</td>
<td>2.5×10⁶</td>
<td>p24 ELISA or Tzm-bl</td>
<td>–</td>
</tr>
<tr>
<td>49</td>
<td>Chronic rCD4 T cells</td>
<td>Immobilized anti-CD3/CD28</td>
<td>5x 10⁶ CD8dPBMCs activated with PHA (4 donors)</td>
<td>21</td>
<td>5</td>
<td>3</td>
<td>4-9</td>
<td>1-3×10⁶</td>
<td>12-40×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>53–60, 64</td>
<td>rCD4 or CD4 T cells</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ CD8dPBMCs activated with PHA + IL-2 (1 donor)</td>
<td>21-28</td>
<td>3-4</td>
<td>2 or 5</td>
<td>Variable</td>
<td>5×10⁶</td>
<td>&gt;90×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>63</td>
<td>rCD4 T cells</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ CD8dPBMCs activated with PHA + IL-2 (1 donor)</td>
<td>21-28</td>
<td>3-4</td>
<td>2 or 5</td>
<td>Variable</td>
<td>5×10⁶</td>
<td>&gt;90×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>58, 59, 60</td>
<td>rCD4 T cells + Int 6 RT inhibitor</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ CD8dPBMCs activated with PHA + IL-2 (1 donor)</td>
<td>21-28</td>
<td>3-4</td>
<td>2 or 5</td>
<td>Variable</td>
<td>5×10⁶</td>
<td>&gt;90×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4, 9</td>
<td>Acute/ Chronic CD8dPBMCs</td>
<td>Immobilized anti-CD3/CD28</td>
<td>5x 10⁶ CD8dPBMCs activated with PHA (4 donors)</td>
<td>21</td>
<td>5</td>
<td>3</td>
<td>4-9</td>
<td>1-3×10⁶</td>
<td>12-40×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>69</td>
<td>Chronic CD4 T cells</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ or 2.5×10⁶ MOLT-4/CCR5</td>
<td>14</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>1×10⁶</td>
<td>2.5×10⁶</td>
<td>RT-PCR (50µl)</td>
<td>ZR-96 Viral RNA Kit (Zymo Research)</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Chronic CD4 T cells</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ or 2.5×10⁶ MOLT-4/CCR5</td>
<td>14</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>1×10⁶</td>
<td>2.5×10⁶</td>
<td>RT-PCR (50µl)</td>
<td>Hologic</td>
<td>–</td>
</tr>
<tr>
<td>69</td>
<td>Chronic CD4 T cells</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ or 2.5×10⁶ MOLT-4/CCR5</td>
<td>14</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>1×10⁶</td>
<td>2.5×10⁶</td>
<td>RT-PCR (50µl)</td>
<td>Hologic</td>
<td>–</td>
</tr>
<tr>
<td>69</td>
<td>Chronic CD4 T cells</td>
<td>PHA-irradiated PBMCs (5-fold excess)</td>
<td>1×10⁶ or 2.5×10⁶ MOLT-4/CCR5</td>
<td>14</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>1×10⁶</td>
<td>2.5×10⁶</td>
<td>RT-PCR (50µl)</td>
<td>Hologic</td>
<td>–</td>
</tr>
<tr>
<td>33, 46, 54</td>
<td>rCD4 T cells, resting CD4 T cells: CD8dPBMCs, CD8 depleted PBMCs.</td>
<td>Immobilized anti-CD3/CD28</td>
<td>5x 10⁶ CD8dPBMCs activated with PHA (4 donors)</td>
<td>21</td>
<td>5</td>
<td>3</td>
<td>4-9</td>
<td>1-3×10⁶</td>
<td>12-40×10⁶</td>
<td>p24 ELISA</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Inducible RNA assays (in terminal dilution)

<table>
<thead>
<tr>
<th>References</th>
<th>Subjects</th>
<th>Samples</th>
<th>Activation method</th>
<th>Feeder cells</th>
<th>Duration (days)</th>
<th>Dilutions</th>
<th>Dilution factor</th>
<th>Replicates</th>
<th>Cells 1st dilution</th>
<th>Total cells tested</th>
<th>Detection method</th>
<th>RNA extraction methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>rCD4 T cells</td>
<td>Anti-CD3/CD28 microbeads</td>
<td>-</td>
<td>7</td>
<td>8</td>
<td>3</td>
<td>12</td>
<td>667,000</td>
<td>12×10⁶</td>
<td>RT-qPCR from sup</td>
<td>–</td>
<td>Hologic</td>
</tr>
<tr>
<td>69</td>
<td>Chronic CD4 T cells</td>
<td>Immobilized anti-CD3/CD28</td>
<td>-</td>
<td>3</td>
<td>8</td>
<td>3</td>
<td>12</td>
<td>500,000</td>
<td>9×10⁴</td>
<td>RT-ddPCR from sup</td>
<td>Hologic</td>
<td>–</td>
</tr>
<tr>
<td>76</td>
<td>Early/ Chronic CD4 T cells</td>
<td>PMA+ionomycin</td>
<td>-</td>
<td>0.5</td>
<td>4</td>
<td>3</td>
<td>24</td>
<td>18,000</td>
<td>0.6×10⁴</td>
<td>RT-qPCR from cells</td>
<td>Direct lysis</td>
<td>–</td>
</tr>
</tbody>
</table>

Culture-based assays to measure HIV reservoir

Culture-based assays have been traditionally used to detect outgrowth of replication-competent virus. More recently, new RNA-based culture assays have been developed to quickly measure the inducible HIV RNA reservoir (Figure 1B). Replication-competent proviruses. The QVOA has been considered the gold-standard assay for determining the frequency of CD4+ T cells harboring replication-competent proviruses because replication-competent virus induced ex vivo almost certainly reflects failure to eradicate the virus in vivo. This assay consists of limiting dilutions of resting CD4+ T cells, which are activated using one of several methods, including phytohemagglutinin (PHA) in the presence of irradiated allogeneic PBMCs (8, 10, 57–60) and anti-CD3 and anti-CD28 antibodies (9). This generalized activation reverses latency and reinitiates the production of infectious HIV-1 from CD4+ T cells harboring replication-competent proviruses. Ex vivo viral propagation is mediated by PHA-stimulated CD4+ lymphoblasts obtained from uninfected donors (8, 10, 58–64) or by the 3×3 activation method of uninfected donor blasts (three donors, three activation conditions) (33, 65). After two or three weeks, viral outgrowth is assessed by
an ELISA assay for HIV-1 p24 antigen or a PCR assay for HIV-1 RNA in the culture supernatant. Testing replicates in serial dilutions permits the quantification of latently infected cells because virus released from a single cell can spread through the culture and produce a detectable level of infection. The frequency of infected cells in the original population of CD4\(^+\) T cells, as well as a CI around this frequency, are then estimated based on Poisson statistics (66) and expressed as infectious units per million (IUPM) CD4\(^+\) T cells. Patients on long-term ART typically exhibit IUPM values between 0.1 and 1 — which is, on average, 300-fold less than HIV proviral DNA (8, 10, 61). It is important, especially for eradication studies, to explicitly report the 95% CI for a given IUPM value to allow comparison with infected cell frequency over time or among patients.

Currently, both QVOA and PCR-based methods are commonly used to assess the latent reservoir; however, there is little correlation between these two assays (10). These discrepancies can be attributed to the heterogeneous nature of the proviruses in CD4\(^+\) T cells. Only a small subset of proviruses can be induced to produce replication-competent virions. By sequence, many proviruses should be replication-competent, but these proviruses are not readily inducible in QVOA assays. Additionally, the proportion of sequence-competent but nonreplicating viruses is highly variable among individuals (67). Nevertheless, the majority of proviruses cannot produce replication-competent virus because these proviruses contain large internal deletions, G-to-A hypermutations introduced by apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), or other inactivating mutations (67). Defective proviruses will not produce infectious virus that can be detected by QVOA, but these viruses can be detected by PCR-based assays. Observed differences may also be due to the lack of standardization and differences in QVOA protocols between laboratories (Table 2). For instance, different cell subsets can be used, such as resting or total CD4\(^+\) T cells, to measure the pool of cells harboring replication-competent virus. When using resting CD4\(^+\) T cells to exclude productively infected cells, CD69\(^+\), CD25\(^+\), or HLA-DR/CD4\(^+\) T cells are removed from cell culture; however, those markers not only identify truly activated CD4\(^+\) T cells, but also proliferating cells (HLA-DR\(^+\)) and Tregs (CD25\(^+\)). These cell subsets could also have a relevant contribution to HIV persistence. The activation protocol is also a main difference between the protocols used by different laboratories. Most protocols use PHA plus irradiated CD8-depleted PBMCs, causing high cell density in each well that is aggravated when feeder cells are added. In contrast, activation with anti-CD3/CD28 allows for a better control of cell concentration throughout the culture, which is an important factor in long protocols.

Despite the importance of the QVOA, this assay has several limitations. It is time consuming, labor intensive, and requires large blood volumes, two or three weeks of cell culture, and PBMCs from at least three uninfected blood donors per assay, making the assay relatively expensive. The pooled PBMCs from uninfected donors are required to propagate the HIV-1 released following the reversal of latency, resulting in high variability between experiments and limiting assay throughput. Cell lines such as MOLT-4/CCR5, which expresses high levels of CD4 and supports infection by both X4-tropic and R5-tropic HIV-1, can be used as target cells to amplify viruses that are released from activated, infected CD4\(^+\) T cells instead of uninfected donor cells, thereby providing greater uniformity for QVOA (68, 69). Despite reducing the variability between experiments by using a cell line, large blood volumes from the study subject and the other limitations of QVOA remain.

Not all replication-competent, latently infected cells are induced by the activation stimuli used in QVOA assays. These stimuli may not fully reproduce the complex activation conditions existing in vivo, particularly given the marked immunological heterogeneity of the latent reservoir cells (70). Moreover, the most efficient activation stimuli may vary by anatomic location or CD4\(^+\) T cell phenotype. Additionally, a single round of PHA stimulation is not enough to activate all intact proviruses (67). Thus, some latent viruses capable of generating infectious virions in vivo may not be recoverable in the QVOA.

QVOA also has a limited dynamic range because the levels of HIV provirus in most individuals on ART are close to the limit of detection, even with large blood draws; the 95% CI for individual determinations are usually ±0.7 log IUPM or 5-fold (63). These are additional challenges to observation of reductions in the reservoir during eradication strategies. Rosenbloom et al. have used a statistical approach for optimizing the QVOA experimental design to achieve any desired set of goals regarding sensitivity (determined by cell input) and precision (determined by number of replicates) (71).

Inducible HIV RNA transcription. Several new assays that quantify the inducible HIV reservoir have been developed. These new assays reduce the contribution of most defective genomes, do not rely on an amplification step with virus propagation by coculture, and may have several advantages for measuring the HIV reservoir. First, many latency-reversing agents (LRAs) show a posttranscriptional block (72); therefore, the activity of these compounds requires measurement of HIV-inducible transcription ex vivo (73, 74). Additionally, because the assays that quantify the inducible HIV reservoir have a higher dynamic range than QVOA, such assays could make it easier to detect reductions in the reservoir ex vivo following effective in vivo interventions (75).

Different versions of assays to detect inducible HIV RNA transcription have been described. In general, CD4\(^+\) T cells are maximally activated as they are for QVOA, and then HIV RNA is directly measured from cell extracts (caRNA) (51, 69, 73–75) or cell supernatants (cell-free RNA [cfRNA]) (69, 73, 74). While caRNA measures transcriptionally competent provirus, it might also detect defective transcripts. cfRNA reflects the capacity to induce translation and form and release virions. In contrast to QVOA, various activation stimuli have been used in these assays, including anti-CD3/CD28 costimulation (17, 73), phosphatidylmyristate (PMA) and ionomycin (74–76), or PHA (51). Moreover, depending on the aim of the study, the format of the assay can be adapted easily. For example, a limiting dilution assay would be employed to measure the frequency of CD4\(^+\) T cells carrying inducible HIV provirus (17, 73, 76), while bulk activation of CD4\(^+\) T cells could be useful for a qualitative assay to test various concentrations of LRAs (74, 75), significantly reducing the cost of the assay.
For caRNA, ms- and usRNA transcripts can be measured by qRT-PCR (51, 56, 76) or ddPCR (17). After HIV transcription is induced, msRNA transcripts are generated, but as the replication cycle continues, the transcripts are increasingly exported as us- and single-spliced mRNA species. Interestingly, the majority of defective HIV genomes contain deletions in the Tat and Rev genes (67), indicating that transcripts from these genes are unlikely to be generated in cells harboring defective proviruses. Procopio et al. proposed the Tat/Rev-induced limiting dilution assay (TILDA) to measure caRNA. This assay uses small blood volumes (10 ml) and is relatively easy to perform without the expense and labor intensiveness of QVOA, making it an attractive option for assessing HIV persistence (76). However, similar to the QVOA, this assay relies on a single round of T cell activation (underestimating the HIV reservoir), and it can potentially measure transcripts derived from some defective proviruses, thereby overestimating the frequency of infected cells with replication-competent virus.

Despite the advantage of cfRNA over caRNA, the latter is more sensitive than the former (69, 73). Indeed, Cillo et al. showed that a mean of 1.5% of proviruses in CD4+ T cells produced detectable levels of cfRNA (viriions) after full activation with anti-CD3/CD28 antibodies, while a mean of 7% of proviruses in CD4+ T cells were reactivated to produce us-caRNA (56). This study confirmed that the large majority of proviruses (98.5%) are not induced to produce virions with T cell activation. The approaches that will prove to have the best performance characteristics — and will correlate best with the actual HIV reservoir that needs to be reduced — remain important areas for future investigation.

Murine viral outgrowth assay
Transfer of infectious tissues between species can result in enhanced viral amplification and has been used historically to identify numerous pathogens using embryonated hen eggs or for the diagnosis of rabies virus (77, 78). Also, the adoptive transfer of PBMCs from ART-suppressed SIV-infected monkeys into uninfected monkeys is a sensitive method for detecting residual virus (79–81). Because humanized mice can be infected with HIV-1 (82), a new VOA was developed using mice to detect replication-competent virus: the murine VOA (83). In murine VOA, cells or tissues from HIV-1-infected subjects with undetectable plasma viral loads are transferred as xenografts into immunocompromised mice. Viral load is then monitored using qPCR. Virion production was detectable by murine VOA within 4 weeks in all subjects on long-term ART (83), consistent with the occurrence of viremia following interruption of ART in patients who initiated treatment during the chronic phase of HIV infection (84). Although murine VOA is not quantitative, it is more sensitive than the standard QVOA performed in parallel in the same subjects. The higher sensitivity of murine VOA compared with QVOA could be explained by a number of factors, including the ability to screen large numbers of host cells (up to 60 million per mouse) and xenogeneic human anti-mouse responses that lead to the activation of human CD4+ T cells. This method may have utility when ex vivo assays cannot detect latent infection in order to obviate an unnecessary treatment interruption; however, it is not readily amenable to quantitation.

Latency in cells other than CD4+ lymphocytes
The CD4+ lymphocyte is the cell documented to harbor the HIV reservoir. What is not known is whether additional cells are lurking in the background, obscured by this larger and proven reservoir. One other cell type, the macrophage and its related cell types like microglia, express the CD4 receptor and have been well documented to be host cells for HIV replication in vivo (85). In vitro and in vivo, HIV-infected macrophages can produce virus and survive for months: a much longer half-life than the productively infected lymphocyte. It has not been definitively determined whether HIV-infected macrophages in patients receiving effective ART produce virus with a prolonged but finite half-life or whether cells of this lineage include a reservoir of truly replication-competent, latently infected cells (85). Clinical studies of latency have focused on CD4+ lymphocytes from the blood and occasionally from tissues. The role of cells of the macrophage lineage represents not only an important biological question, but also an important practical challenge for measuring the latent reservoir. It will be necessary to investigate cells other than CD4+ lymphocytes and tissues other than blood, especially the CNS. Also of note, the problem of measuring DNA in CD4+ lymphocytes is further compounded in macrophages, which may contain viral DNA and protein as a result of their phagocytic function, rather than their role in replication (86).

The reservoir in tissues other than blood
The normal distribution of lymphocytes is 2% in the circulation and 98% in the lymphoid tissues. With HIV infection–induced immune activation, the distribution shifts to 1% and 99%, respectively (87). Therapy largely corrects this shift and results in redistribution of mostly CD45RO+ memory T cells from the lymphoid tissue back to the circulation (5, 88). The dense concentration of lymphoid cells promotes the cell-to-cell spread of HIV in anatomical compartments (89); consequently, the distribution of T cell subsets and the proportion of CD4+ lymphocytes that are latently infected may be higher in tissues than in the circulation (90, 91). Thus, measurements of the latent reservoir from blood represent a population that must be cleared to achieve a cure, but this population is a small and unrepresentative portion of the total reservoir.

Extracirculatory tissues are more difficult to access than blood and harbor latent infection that is not mixed and homogeneously distributed, as in blood. In addition to the large amount of lymphoid tissue in the body, two anatomic compartments — the CNS and the genital tract — have been shown to permit compartmental evolution and occasionally escape from the effective suppression of replication as measured in the blood (92–96). These two anatomic compartments differ from the rest of the body in being both pharmacologic and immunologic sanctuaries for HIV, and, in the case of the CNS, containing a large proportion of cells of the macrophage lineage. These differential selective pressures can account for independent evolution and replication during therapy. The practical issue for measuring the latent reservoir in these extracirculatory tissues is more attributable to the difficulty of obtaining these tissues than to assays different from the ones already described.
Conclusions

The emerging interest in developing safe and affordable curative strategies to eliminate the need of lifelong therapy while improving the health of infected subjects and reducing the risk of viral transmission to uninfected individuals requires better assays to measure the latent reservoir. The actual latent reservoir is smaller than the proviral DNA population but larger than what is measured with the standard QVOA (10). The QVOA provides a minimal estimate of reservoir size; however, it does not successfully detect all the cells containing replication-competent virus after a single round of activation (67). In the context of eradication studies, this underestimation of the HIV reservoir is misleading if the absence of detection is interpreted as the detection of absence. The “Boston” patients (97) and the “Mississippi baby” (98) confirmed that the latent reservoir can persist below the limit of detection of current assays, allowing the infection to recur months to years later. As with remission after cancer chemotherapy, although no residual malignant disease can be detected, it can persist and recur years later.

Recently developed assays measuring induced RNA promise to be faster, more sensitive and precise, less demanding of blood volume, less expensive, and capable of higher throughput than the standard QVOA; however, these assays must be thoroughly validated and standardized between laboratories. First, characterization of the performance of all assays is needed. Second, blinded assay comparisons are necessary to assess their relative performance characteristics with well-defined specimens. Such studies will provide important information regarding the most sensitive and specific assays that could be used in future eradication studies and would be useful in evaluating the qualities and features that would be necessary in a unique assay to measure the true size of the latent reservoir. Therefore, the creation of a consortium to specifically standardize the selected assay between laboratories would be fundamental, in terms of sample preparation, development of standard operating procedures (SOP), and data analysis.

Despite all the efforts in this area, other questions regarding the measurement of the latent reservoir remain open. Is it possible to reactivate all intact proviruses ex vivo? If not, what stimulation would maximally reactivate the latent reservoir? Similarly, the use of frozen samples would be the most convenient way to assess the decay of the latent reservoir in large eradication studies; however, is the quantification of the latent reservoir equally efficient in fresh and frozen samples? When studying eradication candidates, the shock-and-kill effect can be measured with inducible RNA-assays (HIV reactivation) and QVOA (decrease of infected cells), respectively. However, successful HIV cure strategies need to rely on host anti-HIV immune responses and parallel assessments of virological and immunological responses in order to accelerate the development of successful therapies for a functional cure. Despite all these concerns and unresolved questions, the validation of assays will be greatly facilitated by having an effective intervention on which these assays can be compared.

Acknowledgments

This work was supported by the Collaboratory for AIDS Research on Eradication (CARE; U19 AI096113), the UCSD Center for AIDS Research (AI306214), the Department of Veterans Affairs, and the James B. Pendleton Charitable Trust. M. Massanella is supported by a Beatriz de Pinos (AGAUR) post-doctoral fellowship.

Address correspondence to: Douglas D. Richman, University of California San Diego and VA San Diego Healthcare System, Room 329, Stein Clinical Sciences Building, 9500 Gilman Drive, La Jolla, California 92039-0679, USA. Phone: 858.552.7439; E-mail: drichman@ucsd.edu.

27. Bushman F. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. AIDS. 2003;17(5):749–750.
66. Weinberger AD, Weinberger LS. Stochastic